Skip to main content
SpringerLink
Log in

Heterogeneity of biological bone markers in Idiopathic Male Osteoporosis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

In men with idiopathic osteoporosis, histomorphometric studies reported both increased resorption and decreased remodeling. We aimed at examine bone remodeling in these patients by biological marker measurement. We compared pre-treatment carboxy-terminal cross-linking telopeptide of type I collagen (CTX) and bone alkaline phosphatase (bALP) levels in 49 men, mean age 59 ± 14 year, with idiopathic osteoporosis with fractures (40 patients) or osteoporosis diagnosed by densitometry (9 patients) with 50 age-matched controls. The influence of baseline remodeling level on alendronate efficacy was studied. Bone remodeling markers (CTX and bALP) did not significantly differ between patients and controls and were correlated in both groups. There was no correlation between these markers, vitamin D and PTH levels. Twenty-one patients underwent repeat densitometry after 1 year of alendronate (70 mg/week). Mean annual BMD increase, spine +4.1 ± 3.9%, and hip +1.5 ± 1.2% showed no correlation with baseline CTX. Bone remodeling is very heterogeneous and formation and resorption remain biologically coupled in both idiopathic male osteoporosis and controls. Baseline remodeling level does not affect the action of alendronate on BMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Seeman E (1995) The dilemma of osteoporosis in men. Am J Med 98:76S–88S

    Article  PubMed  CAS  Google Scholar 

  2. Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474–1482

    Article  PubMed  CAS  Google Scholar 

  3. Seeman E (2001) Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord 2:45–64

    Article  PubMed  CAS  Google Scholar 

  4. Bilezikian JP (1999) Osteoporosis in men. J Clin Endocrinol Metab 84:3431–3434

    Article  PubMed  CAS  Google Scholar 

  5. Haney EM, Bliziotes MM (2008) Male osteoporosis: new insights in an understudied disease. Curr Opin Rheumatol 20:423–428

    Article  PubMed  Google Scholar 

  6. Boonen S, Kaufman JM, Goemare S, Bouillon R, Vanderschuren D (2001) The diagnosis and treatment of male osteoporosis: defining, assessing, and preventing skeletal fragility in men. Calcif Tissue Int 69:209–213

    Article  Google Scholar 

  7. Grisso JA, Chiu GY, Maislin G, Steinmann WC, Portale J (1991) Risk factors for hip fractures in men: a preliminary study. Bone 8:865–868

    Google Scholar 

  8. Seeman E, Melton LJ, O’Fallon WM, Riggs BL (1983) Risk factors for osteoporosis in men. Am J Med 75:977–983

    Article  PubMed  CAS  Google Scholar 

  9. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E (2006) Bone fragility in men–where are we? Osteoporosis Int 17:1577–1583

    Article  CAS  Google Scholar 

  10. Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Wilvonseder R, Peterlik M (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31:444–451

    Article  PubMed  CAS  Google Scholar 

  11. Lormeau C, Soudan B, d’Herbomez M, Pigny P, Duquesnoy B, Cortet B (2004) Sex-hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone 34:933–939

    Article  PubMed  CAS  Google Scholar 

  12. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP (1997) Insulin-like growth factor-1 in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799–2805

    Article  PubMed  CAS  Google Scholar 

  13. Cohen-Solal ME, Baudoin C, Omouri M, Kuntz D, De Vernejoul MC (1998) Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res 13:1909–1914

    Article  PubMed  CAS  Google Scholar 

  14. Chavassieux P, Meunier PJ (2001) Histomorphometric approach of bone loss in men. Calcif Tissue Int 69:209–213

    Article  PubMed  CAS  Google Scholar 

  15. Delichatsios HK, Lane JM, Rivlin RS (1995) Bone histomorphometry in men with spinal osteoporosis. Calcif Tissue Int 56:359–363

    Article  PubMed  CAS  Google Scholar 

  16. Pernow Y, Hauge EM, Linder K, Dahl E, Saaf M (2009) Bone histomorphometry in male with idiopathic osteoporosis. Calcif Tissue Int 84:430–438

    Article  PubMed  CAS  Google Scholar 

  17. Seibel MJ (2006) Biochemical markers of bone turnover Part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27:123–138

    PubMed  Google Scholar 

  18. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone changes in postmenopausal women: results from the PEPI trial. J Bone Miner Res 14:1583–1595

    Article  PubMed  CAS  Google Scholar 

  19. Nguyen TV, Meier C, Center JR, Eisman JA, Seibel MJ (2007) Bone turnover in elderly men: relationship to change in bone mineral density. BMC Musculoskelet Disord 8:13–15

    Article  PubMed  Google Scholar 

  20. Donescu OS, Battie MC, Videman T, Ristell J, Eyre D (2006) The predictive role of bone turnover markers for BMD in middle-aged men. Aging Male 9:97–102

    Article  PubMed  CAS  Google Scholar 

  21. Szulc P, Delmas PD (2001) Biochemical markers of bone in men. Calcif Tissue Int 69:229–234

    Article  PubMed  CAS  Google Scholar 

  22. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642–1650

    Article  PubMed  CAS  Google Scholar 

  23. Resch H, Pietschmann P, Woloszczuk W, Krexner E, Bernecker P, Willvonseder R (1992) Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest 22:542–545

    Article  PubMed  CAS  Google Scholar 

  24. Szulc P, Kaufman JM, Delmas PD (2007) Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 18:1451–1461

    Article  PubMed  CAS  Google Scholar 

  25. Orwoll E, Ettinger M, Weis S, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    Article  PubMed  CAS  Google Scholar 

  26. Zhong ZM, Chen JT (2009) Anti-fracture efficacy of Risedronic acid in men: a meta-analysis of randomized controlled trials. Clin Drug Investig 29:349–357

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Centre de Rhumatologie, CHU Purpan, 1 Place du Dr Baylac, 31059, Toulouse Cedex, France

    Michel Laroche

Authors
  1. Michel Laroche
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Laroche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laroche, M. Heterogeneity of biological bone markers in Idiopathic Male Osteoporosis. Rheumatol Int 32, 2101–2104 (2012). https://doi.org/10.1007/s00296-011-1930-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1930-y

Keywords

Search

Navigation